to expedite bringing to market of its dipstick-based test for simultaneous identification of a large number of genetic variants of [...]
“Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants” [...]
“Seattle researchers zero in on COVID virus mutation that could be driving spread of new variants” [...]
Click here to view the Medscape Press [...]
https://www.prnewswire.com/news-releases/id-genomics-clonet-e-coli-assay-in-development-to-combat-antibiotic-resistant-urinary-tract-infections-300887699.html SEATTLE (19 July 2019) – ID Genomics, SPC today announced the completion of its first Pre-Submission meeting with the Food and Drug [...]
Social Purpose Corporation Statement (2018) Antimicrobial resistance threatens the very core of human healthcare. ID Genomics’ Social Purpose is simple: to limit bacterial resistance and preserve antibiotics for the good of mankind. We believe that antimicrobial resistance connects every [...]
Today, Seattle-based ID Genomics, Inc.was awarded a grant from the Longitude Prize Discovery Awards, a seed funding program to help teams competing to win the prestigious Longitude Prize. Run by innovation foundation Nesta and supported by Innovate UK as funding partner, the Longitude Prize is a [...]
Many thanks to Clare McGrane at Geek Wire for her narrative describing ID Genomics’ fingerprinting technology. Please read the full article at the link provided here [...]
ID Genomics and the University of Washington have long collaborated on developing cutting-edge technology that improves prescriptions of antibiotics for infectious diseases. To find out more about this collaboration, please read the UW Daily’s account of our technology here: [...]
Many thanks to the Seattle Times for its coverage of ID Genomics’ technology. Please read the full text here: Seattle health startup speeds up lab tests to improve use of antibiotics [...]